Stock News

As Biocryst Pharmaceuticals (BCRX) Stock Price Declined, Holder Longwood Capital Partners Has Trimmed Its Stake by $385,200; Knott David M Has Decreased Its Ligand Pharmaceuticals (LGND) Holding by $4.78 Million as Market Value Rose

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Logo

Longwood Capital Partners Llc decreased its stake in Biocryst Pharmaceuticals (BCRX) by 9.67% based on its latest 2017Q4 regulatory filing with the SEC. Longwood Capital Partners Llc sold 96,300 shares as the company’s stock declined 0.98% with the market. The institutional investor held 900,000 shares of the health care company at the end of 2017Q4, valued at $4.42 million, down from 996,300 at the end of the previous reported quarter. Longwood Capital Partners Llc who had been investing in Biocryst Pharmaceuticals for a number of months, seems to be less bullish one the $499.93 million market cap company. The stock increased 0.40% or $0.02 during the last trading session, reaching $5.07. About 220,364 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined 43.31% since April 28, 2017 and is downtrending. It has underperformed by 54.86% the S&P500.

Knott David M decreased its stake in Ligand Pharmaceuticals Incorporated (LGND) by 4.4% based on its latest 2017Q4 regulatory filing with the SEC. Knott David M sold 35,156 shares as the company’s stock rose 20.51% while stock markets declined. The institutional investor held 762,944 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $104.47M, down from 798,100 at the end of the previous reported quarter. Knott David M who had been investing in Ligand Pharmaceuticals Incorporated for a number of months, seems to be less bullish one the $3.34B market cap company. The stock decreased 0.71% or $1.13 during the last trading session, reaching $157.49. About 164,127 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since April 28, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on May, 8. They expect $1.11 EPS, up 184.62% or $0.72 from last year’s $0.39 per share. LGND’s profit will be $23.53M for 35.47 P/E if the $1.11 EPS becomes a reality. After $1.03 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 7.77% EPS growth.

Knott David M, which manages about $251.42M US Long portfolio, upped its stake in Macquarie Infrastructure Corporation (NYSE:MIC) by 120,000 shares to 132,300 shares, valued at $8.49 million in 2017Q4, according to the filing.

Since December 20, 2017, it had 0 insider purchases, and 12 insider sales for $16.28 million activity. Aryeh Jason sold $1.32M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Thursday, March 8. LAMATTINA JOHN L sold 3,335 shares worth $536,604. $832,824 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by FOEHR MATTHEW W. On Monday, April 2 the insider KOZARICH JOHN W sold $401,063. Davis Todd C sold $2.62 million worth of stock. Sabba Stephen L also sold $126,956 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, December 20.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 29 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was initiated by Stephens with “Overweight” on Wednesday, April 13. The rating was maintained by Roth Capital on Monday, September 21 with “Buy”. The stock has “Buy” rating by Roth Capital on Friday, March 11. The firm earned “Hold” rating on Tuesday, August 8 by Deutsche Bank. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by Roth Capital on Monday, February 26. Roth Capital maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) rating on Wednesday, September 30. Roth Capital has “Buy” rating and $140 target. The firm earned “Sell” rating on Monday, November 20 by Deutsche Bank. Roth Capital maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Friday, December 18 with “Buy” rating. On Thursday, November 9 the stock rating was maintained by H.C. Wainwright with “Buy”. On Thursday, February 22 the stock rating was maintained by Craig Hallum with “Buy”.

Investors sentiment decreased to 1.25 in Q4 2017. Its down 0.44, from 1.69 in 2017Q3. It is negative, as 21 investors sold LGND shares while 86 reduced holdings. 31 funds opened positions while 103 raised stakes. 22.68 million shares or 0.37% less from 22.76 million shares in 2017Q3 were reported. Atlantic Gru Limited, a Georgia-based fund reported 146,832 shares. Comerica State Bank invested 0.03% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Deutsche Natl Bank Ag owns 0.04% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 471,203 shares. 336,935 were reported by Wells Fargo Mn. Regions Financial has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Credit Suisse Ag stated it has 37,270 shares or 0% of all its holdings. Northern Trust Corp owns 311,584 shares or 0.01% of their US portfolio. Tygh Cap reported 48,837 shares. The Texas-based Teacher Retirement System Of Texas has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Invesco Ltd reported 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Cypress Capital Mngmt Limited Com (Wy) invested in 0% or 15 shares. New York-based Capstone Investment Advsrs has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Moreover, Rice Hall James & Assocs Lc has 1.65% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 1,056 are held by Assetmark. Pub Sector Pension Investment Board invested in 17,887 shares.

Investors sentiment decreased to 1.61 in Q4 2017. Its down 0.08, from 1.69 in 2017Q3. It fall, as 16 investors sold BCRX shares while 20 reduced holdings. 22 funds opened positions while 36 raised stakes. 87.26 million shares or 9.34% more from 79.80 million shares in 2017Q3 were reported. Fin Architects reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Alliancebernstein Ltd Partnership, a New York-based fund reported 99,420 shares. Northern Tru reported 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Ra Cap Mgmt Limited Liability Corporation invested 2.87% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Schwab Charles Inv Mgmt Incorporated holds 496,792 shares. Group Inc One Trading LP holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 1,394 shares. Alps Advisors invested in 0% or 109,044 shares. Metropolitan Life Insurance New York invested in 26,823 shares. Invesco Limited owns 956,493 shares. Georgia-based Voya Management Limited Liability Corp has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Sei Invests holds 0% or 588 shares. Vanguard Group reported 5.78 million shares. Franklin Street Advsrs Inc Nc owns 49,000 shares for 0.04% of their portfolio. Advisory Net Limited Co has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 4.75 million are owned by Great Point Prtnrs Ltd Liability.

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals had 34 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Wednesday, September 9. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Hold” rating given on Tuesday, February 9 by Needham. The rating was maintained by JMP Securities on Tuesday, November 28 with “Buy”. The company was maintained on Tuesday, February 9 by Rodman & Renshaw. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Market Outperform” rating by JMP Securities on Friday, December 16. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Sell” rating by Zacks on Friday, August 7. The firm has “Buy” rating by Noble Financial given on Friday, May 26. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Outperform” rating by FBR Capital on Tuesday, February 9. The rating was downgraded by Jefferies to “Buy” on Tuesday, February 9. The stock has “Overweight” rating by JP Morgan on Wednesday, September 6.

Longwood Capital Partners Llc, which manages about $529.67M US Long portfolio, upped its stake in Teladoc Inc (Put) by 10,000 shares to 40,000 shares, valued at $1.39 million in 2017Q4, according to the filing. It also increased its holding in Kadmon Hldgs Inc by 1.58 million shares in the quarter, for a total of 4.92 million shares, and has risen its stake in Seattle Genetics Inc (Call) (NASDAQ:SGEN).

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *